GuidelineArthritis care & research2022
2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging.
Guideline in Arthritis care & research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Utilization of Rehabilitation Services Among People With Common Autoimmune Rheumatic Diseases: A Systematic Review.Arthritis care & research · 2026Pooled it
- Digital health tools in juvenile idiopathic arthritis: a systematic literature review.Pediatric rheumatology online journal · 2025Pooled it
- Bone and growth safety profiles of biologic and conventional DMARDs in juvenile idiopathic arthritis: a 21-year FAERS disproportionality analysis.Inflammopharmacology · 2026Article
- Post-COVID Multisystem Inflammatory Syndrome in Children with Kawasaki-like Features: A Scoping Review of Middle Eastern Evidence.Medicina (Kaunas, Lithuania) · 2026Article
- Article
- Holistic management of juvenile idiopathic arthritis across all ages: British Society for Rheumatology Guideline scope.Rheumatology advances in practice · 2026Review
- Navigating the Biosimilars from Bench to Bedside in Juvenile Idiopathic Arthritis.Paediatric drugs · 2025Review
- A Case Series and Review of Hydroxychloroquine Toxicity and Monitoring: How Do We Dose Hydroxychloroquine?Cureus · 2025Article
- Hot, swollen or stiff joints in children and young people: British Society for Rheumatology guideline scope.Rheumatology advances in practice · 2025Review
- Global burden and genetic insights of RA and JIA in ages 0-19 years: GBD 2021 and MR analysis.Frontiers in immunology · 2025Article
- Biologic and targeted synthetic DMARD safety in inflammatory arthritis: British Society for Rheumatology guideline scope.Rheumatology advances in practice · 2025Review
- Physical activity in children with juvenile idiopathic arthritis: a review of recent literature.Reumatologia · 2025Review
- Impact of the COVID-19 pandemic on the quality of care for juvenile idiopathic arthritis patients: insights from Thailand.Orphanet journal of rare diseases · 2024Article
- Juvenile Idiopathic Arthritis.Indian journal of pediatrics · 2024Review
- Asymptomatic intraspinal epidermoid cyst in a 7-year-old male with juvenile idiopathic arthritis identified by an advanced physiotherapist practitioner: a case report.The Journal of manual & manipulative therapy · 2024Article
- Paediatric Rheumatology Fails to Meet Current Benchmarks, a Call for Health Equity for Children Living with Juvenile Idiopathic Arthritis, Using Digital Health Technologies.Current rheumatology reports · 2024Review
- Level and correlates of physical activity among children and adolescents with juvenile idiopathic arthritis compared to controls: results from a German nationwide prospective observational cohort study.Pediatric rheumatology online journal · 2024Observational
- The prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs: British Society for Rheumatology guideline scope.Rheumatology advances in practice · 2024Review
- Ultrasound and MRI of the foot in children and adolescents newly diagnosed with juvenile idiopathic arthritis.Journal of ultrasonography · 2023Article
- Arthritis Among Children and Adolescents Aged <18 Years - United States, 2017-2021.MMWR. Morbidity and mortality weekly report · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors at 20 institutions in 2 countries.
Funding
Abstract
objectiveTo provide recommendations for the management of juvenile idiopathic arthritis (JIA) with a focus on nonpharmacologic therapies, medication monitoring, immunizations, and imaging, irrespective of JIA phenotype.
methodsWe developed clinically relevant Patient/Population, Intervention, Comparison, and Outcomes questions. After conducting a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation approach was used to rate the quality of evidence (high, moderate, low, or very low). A Voting Panel including clinicians and patients/caregivers achieved consensus on the direction (for or against) and strength (strong or conditional) of recommendations.
resultsRecommendations in this guideline include the use of physical therapy and occupational therapy interventions; a healthy, well-balanced, age-appropriate diet; specific laboratory monitoring for medications; widespread use of immunizations; and shared decision-making with patients/caregivers. Disease management for all patients with JIA is addressed with respect to nonpharmacologic therapies, medication monitoring, immunizations, and imaging. Evidence for all recommendations was graded as low or very low in quality. For that reason, more than half of the recommendations are conditional.
conclusionThis clinical practice guideline complements the 2019 American College of Rheumatology JIA and uveitis guidelines, which addressed polyarthritis, sacroiliitis, enthesitis, and uveitis, and a concurrent 2021 guideline on oligoarthritis, temporomandibular arthritis, and systemic JIA. It serves as a tool to support clinicians, patients, and caregivers in decision-making. The recommendations take into consideration the severity of both articular and nonarticular manifestations as well as patient quality of life. Although evidence is generally low quality and many recommendations are conditional, the inclusion of caregivers and patients in the decision-making process strengthens the relevance and applicability of the guideline. It is important to remember that these are recommendations. Clinical decisions, as always, should be made by the treating clinician and patient/caregiver.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.